Jon Edelson, MD, is the Chairman, CEO, and President of Eirion Therapeutics
What’s Next for ET-02? CEO of Eirion, Jon Edelson, MD, Shares Phase 2 Plans
“As good as we saw results in 1 month, we think we'll see even more remarkable results over the 6 months of treatment,” Edelson said in an interview with Dermatology Times.
The Unprecedented Phase 1 Results of ET-02 for the Treatment of Androgenic Alopecia
Jon Edelson, MD, CEO of Eirion, confirms that topical ET-02 is a completely new approach to treating this type of hair loss.